FDA says its mifepristone safety review will run into 2027
Optogenetic gene therapy partially restores light sensitivity in advanced retinitis pigmentosa, the FDA says its mifepristone safety review will run into 2027, and WHO issues its first child obesity guideline.
First-in-human optogenetic therapy partially restores light sensitivity in blind patients
A first-in-human optogenetic therapy partially restores light sensitivity in blind patients, Kenya confirms its first Ebola case, and the FDA approves tucatinib for HER2-positive breast cancer maintenance.